Benzinga | Apr 26, 2021 10:07AM EDT

22nd Century Group Says Has Fulfilled Order For 3.6M Of Variable Nicotine Content Research Cigarettes For Independent Scientific Studies; Financial Details Not Disclosed

22nd Century Group, Inc. (NYSE:XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it has fulfilled an order for 3.6 million of its variable nicotine content research cigarettes. These research cigarettes are destined for use in important independent, scientific studies funded largely by the U.S. Food and Drug Administration (FDA), and other federal government health agencies. Research already completed using 22nd Century's variable nicotine content research cigarettes has revealed substantial public health benefits for implementing a national standard requiring all cigarettes to contain "minimally or non-addictive" levels of nicotine. Notably, 22nd Century's commercially focused VLN(r) cigarettes with 95% less nicotine already achieve this ambitious goal.